These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11207319)

  • 1. Recombinant HIV-1 glycoprotein 120 induces distinct types of delayed hypersensitivity in persons with or without pre-existing immunologic memory.
    Hladik F; Bender S; Akridge RE; Hu YX; Galloway C; Francis D; McElrath MJ
    J Immunol; 2001 Mar; 166(5):3580-8. PubMed ID: 11207319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmid immunization primes unique DTH responses to HIV-1MN envelope epitopes as compared to recombinant protein vaccination.
    Chattergoon MA; Maguire HH; Robinson TM; Serrano E; Boyer JD; Weiner DB
    Hybrid Hybridomics; 2002 Apr; 21(2):117-22. PubMed ID: 12031101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
    McElrath MJ; Corey L; Montefiori D; Wolff M; Schwartz D; Keefer M; Belshe R; Graham BS; Matthews T; Wright P; Gorse G; Dolin R; Berman P; Francis D; Duliege AM; Bolognesi D; Stablein D; Ketter N; Fast P
    AIDS Res Hum Retroviruses; 2000 Jun; 16(9):907-19. PubMed ID: 10875616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed-type hypersensitivity skin testing in human immunodeficiency virus-infected pediatric patients.
    Raszka WV; Moriarty RA; Ottolini MG; Waecker NJ; Ascher DP; Cieslak TJ; Fischer GW; Robb ML
    J Pediatr; 1996 Aug; 129(2):245-50. PubMed ID: 8765622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.
    Katzenstein DA; Kundu S; Spritzler J; Smoller BR; Haszlett P; Valentine F; Merigan TC
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):341-7. PubMed ID: 10634195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection.
    Bonsignori M; Moody MA; Parks RJ; Holl TM; Kelsoe G; Hicks CB; Vandergrift N; Tomaras GD; Haynes BF
    J Immunol; 2009 Aug; 183(4):2708-17. PubMed ID: 19625640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
    Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.
    Jankovic D; Caspar P; Zweig M; Garcia-Moll M; Showalter SD; Vogel FR; Sher A
    J Immunol; 1997 Sep; 159(5):2409-17. PubMed ID: 9278332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
    Evans TG; McElrath MJ; Matthews T; Montefiori D; Weinhold K; Wolff M; Keefer MC; Kallas EG; Corey L; Gorse GJ; Belshe R; Graham BS; Spearman PW; Schwartz D; Mulligan MJ; Goepfert P; Fast P; Berman P; Powell M; Francis D;
    Vaccine; 2001 Feb; 19(15-16):2080-91. PubMed ID: 11228380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.
    Yu HT; Tian D; Wang JY; Guo CX; Li Y; Wang X; Li D; Zhang FM; Zhuang M; Ling H
    PLoS One; 2014; 9(12):e115047. PubMed ID: 25546013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection.
    Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
    APMIS; 2012 Mar; 120(3):204-9. PubMed ID: 22339677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.